%0 Journal Article
%T Direct costs and hospital morbimortality impact from preventable adverse drug events Costos directos e impacto sobre la morbimortalidad hospitalaria de eventos adversos prevenibles a medicamentos en una instituci車n de tercer nivel de Bogot芍
%A Jos谷 Fernando Pinz車n
%A Carlos Maldonado
%A Jorge A. D赤az
%A Omar Segura
%J Biom谷dica
%D 2011
%I Instituto Nacional de Salud
%X Introduction. Implementing pharmacovigilance activities consists of monitoring and assessment of activities related to medical attention. However, additional data are necessary to identify conditions where care quality can be improved. Therefore, a focus on adverse drug events analysis from a prevention and economic perspective is needed, with emphasis on its local impact. Objective. Preventable adverse drug events were summarized to establishing their impact on morbidity and mortality, as well as to estimate the ensuing economic burden. Materials and methods. The data were gathered from a level 3 hospital (high complexity), located in Bogot芍, Colombia, where specific pharmacovigilance activities were recorded in 2007. Patient charts were reviewed to characterize adverse drug events according to their causality, severity and preventability. Direct costs were estimated by grouping diagnostic tests, length of hospitalization, procedures and additional drugs required. Results. The charts of 283 patients and 448 reports were analyzed. These data indicated that 24.8% of adverse drug events were preventable and that an associated mortality of 1.1% had occurred. The associated direct costs were between USD $16,687 and $18,739. Factors more commonly associated with preventability were drug-drug interactions, as well as inappropriate doses and unsuitable frequencies at which the drugs were administrated. Conclusions. The data recommended that actions be taken to decrease preventable adverse drug events, because of negative impact on patient's health, and unnecessary consumption of healthcare resources. Introducci車n. La implementaci車n de actividades de farmacovigilancia permite supervisar y evaluar aspectos relacionados con la atenci車n m谷dica. Es necesario que la informaci車n recolectada permita identificar oportunidades para mejorar la calidad de la atenci車n en salud. Se propone un an芍lisis de los eventos adversos a medicamentos desde la 車ptica preventiva y econ車mica, estableciendo su impacto local. Objetivo. Determinar el porcentaje de eventos adversos prevenibles a medicamentos, reportados en una instituci車n de tercer nivel, para establecer su impacto sobre la morbimortalidad y el econ車mico desde la 車ptica del pagador y mostrando la relevancia de usar un m谷todo que permita identificarlos y evitar o disminuir su presentaci車n. Materiales y m谷todos. A partir de los reportes generados durante actividades de farmacovigilancia en el a o 2007 en un hospital de tercer nivel de Bogot芍, se revisaron las historias cl赤nicas de los pacientes involucrados y se evalu車 la relac
%K toxicidad de medicamentos
%K hospitales
%K costos y an芍lisis de costo
%K estudios de evaluaci車n
%K Colombia
%U http://www.revistabiomedica.org/index.php/biomedica/article/view/320